|1.||Takeda, Ken: 2 articles (06/2009 - 12/2002)|
|2.||Shimizu, Takahisa: 2 articles (06/2009 - 12/2002)|
|3.||Stio, Maria: 2 articles (07/2006 - 03/2002)|
|4.||d'Albasio, Giuseppe: 2 articles (07/2006 - 03/2002)|
|5.||Treves, Cristina: 2 articles (07/2006 - 03/2002)|
|6.||Binderup, Lise: 2 articles (02/2003 - 01/2003)|
|7.||Treves, C: 2 articles (06/2001 - 02/2001)|
|8.||Stio, M: 2 articles (06/2001 - 02/2001)|
|9.||Fazel, Nasim: 1 article (06/2015)|
|10.||Guo, Miao: 1 article (01/2011)|
|1.||Lichen Planus (Lichen Ruber Planus)
10/01/2000 - "KH 1060 for the treatment of lichen planus: a multicenter, randomized, double-blind, vehicle-controlled study."
06/01/2015 - "KH1060, a vitamin D analogue, is not beneficial in the management of cutaneous lichen planus. "
01/01/1998 - "A parallel-group, double-blind, randomised study was performed to establish the effect of the vitamin D3 analogue KH 1060, in an ointment versus vehicle only, on the epidermal cell characteristics of chronic idiopathic lichen planus; KH 1060 also has marked immunosuppressive activity. "
01/01/1998 - "The epidermis of chronic idiopathic lichen planus during topical treatment with the vitamin D3 analogue KH 1060."
|2.||Breast Neoplasms (Breast Cancer)
09/01/1996 - "In human breast cancer cells, MCF-7, the half-maximal gene activation values for KH1060 and seven of its structural precursors were determined on a DR3-type VD response element. "
07/01/1995 - "In conclusion, the data indicate that KH 1060 is an extremely potent 1,25D3 analogue inducing differentiation of all six breast cancer lines and potently inhibiting clonal growth of four of them with concomitant decreased bcl-2 and cell cycle arrest at G0/G1.(ABSTRACT TRUNCATED AT 400 WORDS)"
07/01/1995 - "Dose-response studies showed that KH 1060 was the most potent analogue, because it was able to induce differentiation in all seven breast cancer cell lines (measured by lipid staining) and to suppress more than 50% clonal proliferation (ED50) at 10(-10) M in all cell lines, except MDA-MB-436 and BT-20. "
09/04/1996 - "In human breast cancer MCF-7 cells, we studied the growth-inhibitory activities of a set of 8 analogues that cover conservative structural changes from 20-epi-VD (MC1288) to KH1060. "
07/01/1995 - "We have studied the in vitro biological activities and mechanism of action of 1,25-dihydroxyvitamin D3 (1,25D3) and four potent 1,25D3 analogues [20-epi-22oxa-24a,26a,27a-tri-homo-1,25(OH)2D3 (KH 1060); 20-epi-1,25(OH)2D3; 1,25(OH)2-16ene-D3; and 1,25(OH)2-16ene-23yne-D3] on proliferation and differentiation of estrogen receptor-negative (MDA-MB-436, BT-20, SK-BR-3, and MDA-MB-231), estrogen receptor-weakly positive (BT474), and estrogen receptor-positive (MCF-7) breast cancer cell lines. "
|3.||Osteosarcoma (Osteogenic Sarcoma)
08/01/2003 - "In the present study, 1alpha,25(OH)(2)D(3) and the analogs KH1060, EB1089, and CB1093 were used to study the mechanism of the cell cycle arrest and to compare the effectiveness of these compounds in human MG-63 osteosarcoma cells. "
05/15/1996 - "Collectively, at comparable and lower concentrations, the 20-epi analogs, KH 1060 and MC 1288, mediate much stronger and longer lasting stimulatory effects than calcitriol or its analog MC 903 on target-gene expression associated with the differentiated phenotype of the MG-63 human osteosarcoma cells."
10/01/1995 - "Binding studies to vitamin D receptor protein, from human osteosarcoma MG-63 cells, demonstrated kd values of 8.5 x 10(-11) for 1 alpha,25(OH)2D3, 6.5 x 10(-11) for KH 1060, and 2.7 x 10(-10) for EB 1089. "
05/15/1996 - "We have compared the actions of calcitriol and its three synthetic analogs, 20-epi-22-oxa-24a,26a,27a-trihomo-1 alpha,25-dihydroxyvitamin D3 (KH 1060), 1 alpha,24S-(OH)2-22-ene-26,27-cyclopropyl vitamin D3 (MC 903) and 20-epi-1 alpha,25-dihydroxyvitamin D3 (MC 1288), on the expression of two marker genes of differentiated osteoblasts, namely alkaline phosphatase and osteocalcin, using human MG-63 osteosarcoma cells. "
12/01/1995 - "In vitro bone resorption was 2.3 and 17.5 times more potently stimulated by EB1089 and KH1060, respectively. "
02/01/1995 - "Bone resorption was stimulated by 1,25-(OH)2D3 and analogs in a dose-dependent manner with KH1060 and EB1089 being more potent and 1,25-(OH)2D3. "
10/01/1995 - "Studies on two new vitamin D analogs, EB 1089 and KH 1060: effects on bone resorption and osteoclast recruitment in vitro."
02/01/1995 - "The purpose of the present study was to investigate the effect of tamoxifen on 1,25-(OH)2D3- and analogs (EB1089 and KH1060)-stimulated bone resorption in an in vitro model. "
10/01/1995 - "We have investigated the effects on bone resorption of two new potent antiproliferative vitamin D3 analogs, EB 1089 and KH 1060, by studying recruitment of osteoclasts in murine bone marrow cultures and 45Ca release from prelabeled neonatal mouse calvarial bones. "
06/01/2009 - "Synergistic induction of gene expression during the differentiation into mature macrophage in human myeloblastic leukemia cells treated with TPA and KH1060."
08/01/1996 - "The aim of this study was to evaluate the therapeutic potential of combining a vitamin D(3) analogue, 20-epi-22-oxa-24a,26a,27a-tri-homo-1alpha,25(OH) 2D, (KH 1060), which belongs to the family of potent 20-epi-1,25(OH),D3 analogues, with 9-cis-RA by assessing their effects on the proliferation, differentiation, and apoptosis of the human leukemia cell line HL-60 in vitro. "
03/01/1999 - "A human myeloblastic leukemia cell line, ML-1, was induced to differentiate along the monocytic lineage following exposure to a 1,25-dihydroxyvitamin D3 analogue, 20-epi-22-oxa-24a,26a,27a-tri-homo-1,25-dihydroxyvitam in D3 (KH1060) or 12-O-tetradecanoylphorbol-13-acetate (TPA). "
03/01/1999 - "Vitamin D3 analogue KH1060 combined with TPA synergistically induces mature macrophages in human myeloblastic leukemia ML-1 cells."
06/01/2009 - "Treatment of human myeloblastic leukemia ML-1 cells with the phorbol ester TPA in combination with the vitamin D(3) analogue KH1060 will induce a synergistic differentiation to mature macrophage with multinuclei. "
|3.||Cholecalciferol (Vitamin D3)
|7.||Asp(5)- oxytocin (OXA)
|8.||Tretinoin (Retinoic Acid)
|9.||Estrogen Receptor Modulators (Antiestrogen)
|10.||Calcitriol Receptors (Calcitriol Receptor)
|2.||Islets of Langerhans Transplantation
|3.||Homologous Transplantation (Allograft)
|4.||Heterologous Transplantation (Xenotransplantation)